Protagonist Therapeutics to Present Preclinical Results on PN-943 at the 15th Congress of European Crohn’s and Colitis Organization (ECCO)
- Friday, February 7, 2020, 7:04
- Finance
- Add a comment
NEWARK, Calif., Feb. 7, 2020 /PRNewswire/ — Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company will present preclinical data on PN-943, the Company’s oral, gut-restricted, alpha-4-beta-7 inhibitor candidate therapeutic, at the 15th Congress of the European…
About the Author
adminasapcorp has written 39584 stories on this site.